USA – Roche’s anti-SARS-CoV-2 antibody test granted EUA

  • The FDA authorizes the emergency use of Roche’s (OTCQX:RHHBY +1.9%) Elecsys Anti-SARS-CoV-2 antibody blood test, a semi-quantitative assay that measures the levels of antibodies to the spike protein of the coronavirus.
  • Compared to results from a molecular test, the negative concordance rate (percent agreement) is 99.98% and the positive concordance rate is 96.6% [at least 15 days after diagnosis with a polymerase chain reaction (PCR) test].